

09/ 881 328  
A# 10

# WEST Search History

DATE: Tuesday, December 24, 2002

Set Name Query  
side by side

Hit Count Set Name  
result set

*DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ*

L9	l1 and l2 and L3 and l8	662	L9
L8	permea\$	364738	L8
L7	permeab\$	278905	L7
L6	l1 and l2 and L3	1345	L6
L5	l1 same l2 same L3	44	L5
L4	l1 with l2 with L3	17	L4
L3	vascula\$ or (blood vessel)	97140	L3
L2	parenchyma\$	4612	L2
L1	dna or rna or plasmid or oligonucleotide or polynucleotide or (nucleic acid)	187523	L1

END OF SEARCH HISTORY

**WEST****Print Selection**

---

Select?	Document ID	Section(s)	Page(s)	# Pages to print	Database
<input checked="" type="checkbox"/>	6365575	all	all	28	USPT,PGPB,JPAB,EPAB,DWPI
<input checked="" type="checkbox"/>	6297219	all	all	14	USPT,PGPB,JPAB,EPAB,DWPI
<input checked="" type="checkbox"/>	6177403	all	all	29	USPT,PGPB,JPAB,EPAB,DWPI
<input checked="" type="checkbox"/>	5707969	all	all	12	USPT,PGPB,JPAB,EPAB,DWPI
<input checked="" type="checkbox"/>	5810767	all	all	15	USPT,PGPB,JPAB,EPAB,DWPI
<input checked="" type="checkbox"/>	5328470	all	all	20	USPT,PGPB,JPAB,EPAB,DWPI

**Building****Room****Printer**

cm1



11e14



gbegptr



Generate Collection

Print

## Search Results - Record(s) 301 through 350 of 662 returned.

- 
- ☐ 301. [6455676](#). 25 Apr 00; 24 Sep 02. Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging. Weickert; Michael J., et al. 530/385; C07K014/805.
- 
- ☐ 302. [6455553](#). 03 Oct 00; 24 Sep 02. Method for treating a demyelinating condition. Werner; Peter, et al. 514/356; 514/903. A61K031/44.
- 
- ☐ 303. [6451994](#). 27 Sep 99; 17 Sep 02. 23413, a novel human ubiquitin protease. Kapeller-Libermann; Rosana, et al. 536/23.5; 536/23.1 536/24.3 536/24.31. C07H021/02 C07H021/04.
- 
- ☐ 304. [6451312](#). 20 Jul 99; 17 Sep 02. VEGF-gelonin for targeting the vasculature of solid tumors. Thorpe; Philip E.. 424/183.1; 424/185.1 424/192.1 530/399. A61K039/395 A61K039/00 C07K014/475.
- 
- ☐ 305. [6451044](#). 28 Dec 99; 17 Sep 02. Method and apparatus for heating inflamed tissue. Naghavi; Morteza, et al. 607/96; 623/1.42. A61N001/00.
- 
- ☐ 306. [6448390](#). 20 May 99; 10 Sep 02. Stable envelope proteins for retroviral, viral and liposome vectors and use in gene drug therapy. Albritton; Lorraine Moore, et al. 536/23.72; 435/235.1 536/23.1. C07H021/04 C07H021/02 C12N007/00.
- 
- ☐ 307. [6447771](#). 09 Aug 99; 10 Sep 02. Methods and materials relating to novel CD39-like polypeptides. Ford; John, et al. 424/94.61; A61K038/47.
- 
- ☐ 308. [6444802](#). 30 Sep 99; 03 Sep 02. Human aminopeptidase. Kapeller-Libermann; Rosana, et al. 536/23.2; 435/320.1 435/325 435/69.1 435/810 435/975 536/23.1. C07H021/04 C07H021/02 C12P021/06 C12N015/00 G01N033/53.
- 
- ☐ 309. [6444791](#). 24 Oct 00; 03 Sep 02. Methods and compositions for the treatment of keratoconus using protease inhibitors. Quay; Steven C.. 530/380; 424/450 424/489 424/78.04 424/94.64 424/94.65 424/94.66 424/94.67 530/350 530/381 530/412. A61K035/14 A61K038/16 A61K009/127 C07K014/00 C07K017/00.
- 
- ☐ 310. [6444447](#). 10 Nov 99; 03 Sep 02. Polymer grafting by polysaccharide synthases. DeAngelis; Paul L.. 435/97; 435/101 435/72. C12P019/18.
- 
- ☐ 311. [6440933](#). 01 Sep 98; 27 Aug 02. Compounds and method for the prevention and treatment of diabetic retinopathy. Bodor; Nicholas Stephen, et al. 514/11; 514/15 514/16 514/17 514/2 514/9 530/300 530/317 530/327 530/328 530/345 546/134 546/288 546/290 546/314. A61K038/08 A61K038/12 C07K005/12.
- 
- ☐ 312. [6436708](#). 08 Feb 99; 20 Aug 02. Delivery system for gene therapy to the brain. Leone; Paola, et al. 435/458; 424/450 435/320.1 435/455 514/44. C12N015/88 C12N015/00.
- 
- ☐ 313. [6429200](#). 16 Jul 99; 06 Aug 02. Reverse micelles for delivery of nucleic acids. Monahan; Sean D., et al. 514/44; 424/450 435/455 435/458 536/23.1. A61K031/710 A61K031/711 A61K009/127.
-

- 
- ☐ 314. 6428950. 22 Nov 99; 06 Aug 02. Assay to identify compounds that alter apolipoprotein E expression. Cordell; Barbara, et al. 435/4; 424/570 424/572 424/577 435/7.21 435/70.3 514/1. C12Q001/00 G01N033/567 C12P021/04 A61K035/30 A61K035/12.
- 
- ☐ 315. 6428802. 29 Dec 99; 06 Aug 02. Preparing artificial organs by forming polylayers of different cell populations on a substrate. Atala; Anthony. 424/423; 424/93.7 425/177 425/180 425/395. A61F002/00 C12N011/02 C12N011/08 C12N005/06 C12N005/08.
- 
- ☐ 316. 6425918. 17 Nov 98; 30 Jul 02. Polysaccharide sponges for cell culture and transplantation. Shapiro; Lilia, et al. 623/11.11; 424/426. A61F002/24 A61F002/02.
- 
- ☐ 317. 6420628. 28 Sep 98; 16 Jul 02. Seed shattering. Ulvskov; Peter, et al. 800/278; 435/199 435/419 435/468 435/69.1 536/23.1 536/23.6 536/24.1 800/283 800/287 800/290 800/298 800/306. C12N015/09 C12N015/29 C12N015/82 A01H005/00.
- 
- ☐ 318. 6420153. 01 Nov 00; 16 Jul 02. 18232, a novel dual specificity phosphatase and uses therefor. Meyers; Rachel A., et al. 435/196; 435/252.3 435/320.1 435/325 536/23.1 536/23.2 536/24.1. C12N009/16 C12N001/20 C12N005/00 C07H021/02 C07H021/04.
- 
- ☐ 319. 6416755. 13 Jun 00; 09 Jul 02. Human beta-alanine-pyruvate aminotransferase. Bandman; Olga, et al. 424/94.5; 435/193 435/252.3 435/320.1 536/23.2. A61K038/51 C12N009/10 C12N001/20 C12N015/00 C07H021/04.
- 
- ☐ 320. 6416741. 03 Sep 99; 09 Jul 02. Preparation of further diagnostic agents. Sutton; Andrew Derek, et al. 424/9.52; 516/11 516/77. A61B008/00 B01F017/00.
- 
- ☐ 321. 6413757. 28 Feb 00; 02 Jul 02. 25312, a novel human agmatinase-like homolog. Cook; William James, et al. 435/195; 435/325 435/69.1 536/23.2 536/24.31. C12N009/14 C12N009/62 C12P021/06 C07H021/04.
- 
- ☐ 322. 6406853. 25 Aug 00; 18 Jun 02. Interventions to mimic the effects of calorie restriction. Spindler; Stephen R.. 435/6; 435/5 435/91.1 435/91.2 514/693 514/724. C12Q001/68,
- 
- ☐ 323. 6403358. 05 Oct 99; 11 Jun 02. 21529, a novel adenylate cyclase. Kapeller-Libermann; Rosana, et al. 435/232; 435/252.3 435/320.1 435/325 536/23.2. C12N009/88 C12N015/60 C12N001/21 C12N015/85 C07H021/04.
- 
- ☐ 324. 6399700. 26 Mar 01; 04 Jun 02. Comb copolymers for regulating cell-surface interactions. Mayes; Anne M., et al. 524/731; 427/2.1 427/2.12 427/2.13 435/325 435/373 435/374 435/375 435/378 435/395 435/396 435/402 435/404 524/732 525/165 525/166 525/168 525/54.1 525/54.3. C08J005/24 A61K047/48.
- 
- ☐ 325. 6399585. 23 Apr 98; 04 Jun 02. In Utero treatment of CFTR-related deficiencies. Larson; Janet E., et al. 514/44; 424/93.21 435/320.1 435/325 435/455 435/456 435/69.1. A01N043/04 A61K031/70 C12N015/63 C12N015/09 C12N015/00.
- 
- ☐ 326. 6399575. 10 Nov 99; 04 Jun 02. Methods and compositions for targeting compounds to the central nervous system. Smith; Bruce F., et al. 514/16; 530/329. A61K038/08 C07K007/06.
-

- ☐ 327. [6399078](#). 01 Jun 99; 04 Jun 02. Chemokine--glycosaminoglycan complexes and their use in treating or preventing receptor mediated diseases. Devico; Anthony L., et al. 424/278.1; 424/185.1 424/279.1 514/2 514/56 514/59 514/885. A61K047/00 A61K039/00 A61K045/00 A61K038/00 A61K031/727.
- 
- ☐ 328. [6395749](#). 01 Sep 98; 28 May 02. Carboxamide compounds, methods, and compositions for inhibiting PARP activity. Li; Jia-He, et al. 514/310; 424/485 424/486 424/487 514/253.06 514/307 514/309 514/311 514/312 514/313 514/314 514/82 544/337 544/363 546/141 546/143 546/144 546/146 546/153 546/157 546/158 546/165 546/167 546/169 546/21. A61K031/495 A61K031/47 C07F009/02 C07D217/22 C07D215/16.
- 
- ☐ 329. [6395299](#). 14 Feb 00; 28 May 02. Matrices for drug delivery and methods for making and using the same. Babich; John W., et al. 424/484;. A61K009/14.
- 
- ☐ 330. [6392019](#). 28 Jul 99; 21 May 02. Antibodies specific for EGF motif proteins. Ford; John, et al. 530/387.9; 530/300 530/350 530/387.1 530/388.1 530/389.1. C07K002/00 C07K014/00 C07K016/00 C07K016/18.
- 
- ☐ 331. [6387902](#). 31 Dec 98; 14 May 02. Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP. Zhang; Jie, et al. 514/249; 544/347 544/348. A61K031/50 C07D241/46.
- 
- ☐ 332. [6383811](#). 02 Jan 01; 07 May 02. Polyampholytes for delivering polyions to a cell. Wolff; Jon A., et al. 435/450; 435/458 514/44. A61K009/127.
- 
- ☐ 333. [6383780](#). 19 Nov 99; 07 May 02. 2786, a novel human aminopeptidase. Kapeller-Libermann; Rosana, et al. 435/69.1; 435/252.3 435/320.1 435/325 435/6 536/23.5. C12P021/06.
- 
- ☐ 334. [6380211](#). 15 Nov 00; 30 Apr 02. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity. Jackson; Paul F., et al. 514/309; 514/233.5 544/128 546/141. A61K031/47.
- 
- ☐ 335. [6380193](#). 01 Sep 98; 30 Apr 02. Fused tricyclic compounds, methods and compositions for inhibiting PARP activity. Li; Jia-He, et al. 514/243; 514/249 514/257 514/283 514/286 514/292 514/293 514/296 544/182 544/233 544/234 544/245 544/247 544/250 546/48 546/63 546/81 546/84 546/86 546/98. A61K031/53 A61K031/44 A61K031/50 A61K031/505.
- 
- ☐ 336. [6379966](#). 29 Nov 99; 30 Apr 02. Intravascular delivery of non-viral nucleic acid. Monahan; Sean D., et al. 435/455; 424/450 514/44 536/23.1. C12N015/85 A61K009/48 A61K048/00 C07H021/04.
- 
- ☐ 337. [6375931](#). 14 Apr 99; 23 Apr 02. Contrast agents. O slashed.stensen; Jonny, et al. 424/9.52;. A61B008/00.
- 
- ☐ 338. [6375929](#). 26 Oct 99; 23 Apr 02. Gene therapy for inhibition of angiogenesis. Thomas, Jr.; Kenneth A., et al. 424/9.2; 424/9.1 424/93.1 424/93.2 424/93.6 435/320.1 435/325. A61K049/00 C12N015/861.
- 
- ☐ 339. [6372499](#). 03 May 99; 16 Apr 02. Polymeric complexes for the transfection of nucleic acids, with residues causing the destabilisation of cell membranes. Midoux; Patrick, et al. 435/455; 424/486 435/320.1 435/325 435/69.1. C12N015/88.

- 
- ☐ 340. 6372482. 15 Jul 99; 16 Apr 02. Device and method for performing a biological modification of a fluid. Mitrani; Eduardo N.. 435/284.1; 210/601 210/602 435/1.1 435/347 435/373 435/374. A01N001/02.
- 
- ☐ 341. 6372473. 04 Oct 99; 16 Apr 02. Tissue plasminogen activator-like protease. Moore; Paul A., et al. 435/212; 435/217 530/327 530/328 530/350 530/827 530/828. C12N009/48 C12N009/68 C07K007/09 C07K007/08 C07K004/12.
- 
- ☐ 342. 6369210. 30 Jun 99; 09 Apr 02. 22012, human carboxypeptidase. Kapeller-Libermann; Rosana, et al. 536/23.5; 435/69.1 530/350 536/18.7 536/22.1 536/23.1 536/23.2. C07H021/04 C07H005/04 C07H019/00 C07H021/00.
- 
- ☐ 343. 6367479. 15 Apr 98; 09 Apr 02. METHOD OF FORCING THE REVERSE TRANSPORT OF CHOLESTEROL FROM A BODY PART TO THE LIVER WHILE AVOIDING HARMFUL DISRUPTIONS OF HEPATIC CHOLESTEROL HOMEOSTASIS, AND PHARMACEUTICAL COMPOSITIONS AND KIT RELATED THERETO. Williams; Kevin Jon. 128/898; 424/450. A61F005/56.
- 
- ☒ 344. 6365575. 16 Oct 97; 02 Apr 02. Gene delivery and expression in areas inaccessible to direct protein delivery. Brigham; Kenneth, et al. 514/44; 536/23.5. A61K048/00 C12N015/12.
- 
- ☐ 345. 6362392. 10 Apr 00; 26 Mar 02. Nude mouse model for the growth and treatment of human neurally-derived tumors. Martuza; Robert L., et al. 800/10; 424/9.1 424/9.2 424/93.1 800/8 800/9. A61K049/00 A01K067/00 A01K067/033 A01N063/00.
- 
- ☐ 346. 6361771. 05 Apr 00; 26 Mar 02. ARPE-19 as a platform cell line for encapsulated cell-based delivery. Tao; Weng, et al. 424/93.21; 435/320.1 435/325 435/366 435/371 435/455 604/43 604/890.1 623/4.1. A61K048/00 A61K009/22 C12N015/163 C12N005/108 A61M003/00.
- 
- ☐ 347. 6358954. 09 Nov 99; 19 Mar 02. PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same. Levitzki; Alexander, et al. 514/250; 514/267 544/247 544/251 544/343 544/345. A61K031/495 C07D239/00 C07D491/00 C07D241/36 C07D471/00.
- 
- ☐ 348. 6350754. 12 Jan 00; 26 Feb 02. 3-(cycloalkanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors. Tang; Peng Cho, et al. 514/275; 514/373 514/379 514/403 514/406 514/415 514/418 514/444 514/447 514/469 544/242 544/297 544/322 544/333 544/334 544/335 548/207 548/209 548/241 548/360.1 548/469 548/470 548/483 548/486 549/396 549/407 549/49 549/58. A61K031/404 A61K031/506 A61P061/00 C07D209/34 C07D403/06.
- 
- ☐ 349. 6348186. 05 Jun 95; 19 Feb 02. Preparation of further diagnostic agents. Sutton; Andrew Derek, et al. 424/9.52; 264/12 516/11 516/77. A61B008/00 B01F017/00 B29B009/00.
- 
- ☐ 350. 6348069. 03 Nov 98; 19 Feb 02. Engineering of strong, pliable tissues. Vacanti; Joseph P., et al. 623/11.11; A61F002/02.
- 

[Generate Collection](#)[Print](#)

[Generate Collection](#)[Print](#)**Search Results - Record(s) 551 through 600 of 662 returned.**

- 
- ☐ 551. [5811100](#). 15 May 96; 22 Sep 98. Compounds for the prevention and treatment of helminth infections. Daugalieva; Emma K., et al. 424/194.1; 424/184.1 424/193.1 424/280.1 514/12 514/2 540/575. A61K039/385 A61K039/39 A61K038/00 C07D243/08.
- 
- ☒ 552. [5810767](#). 10 May 96; 22 Sep 98. Method and apparatus for pressurized intraluminal drug delivery. Klein; Enrique J.. 604/509; 604/103.01 604/265 604/523. A61M031/00.
- 
- ☐ 553. [5804428](#). 31 Mar 98; 08 Sep 98. Fibrin sealant compositions and methods for utilizing same. Edwardson; Peter A. D., et al. 435/212; 424/529 424/530 424/94.64 435/214 435/217 514/12 514/2 514/21 514/6 530/381 530/382 530/383 530/384. C12N009/48.
- 
- ☐ 554. [5798209](#). 26 May 95; 25 Aug 98. Human and mouse very low density lipoprotein receptors and methods for use of such receptors. Chan; Lawrence C. B.. 435/6; 435/91.2 536/23.1 536/24.3 536/24.33. C12Q001/68 C12P019/34 C07H021/04 C07H021/02.
- 
- ☐ 555. [5795860](#). 28 Feb 94; 18 Aug 98. Analogs for specific oligosaccharide-protein interactions and uses therefor. Witt; Daniel P., et al. 514/12; 514/2 514/54 514/62 530/350 530/359 536/55.1 536/55.2. A01N037/18 A61K031/70.
- 
- ☐ 556. [5792457](#). 06 Jun 95; 11 Aug 98. Antibody recognizing endothelial cell ligand for leukocyte CR3. Tuomanen; Elaine, et al. 424/139.1; 424/141.1 424/150.1 424/152.1 424/178.1 530/387.9 530/388.4. A61K039/40 A61K039/395.
- 
- ☐ 557. [5789447](#). 12 Sep 95; 04 Aug 98. Nitric oxide releasing compounds as protective agents in ischemia reperfusion injury. Wink, Jr.; David A., et al. 514/611; 514/642. A61K031/40.
- 
- ☐ 558. [5785964](#). 06 Apr 95; 28 Jul 98. Three-dimensional genetically engineered cell and tissue culture system. Naughton; Gail K., et al. 424/93.21; 424/93.1 424/93.2 424/93.3 435/320.1 435/325 800/14. A01N063/00 C12N005/10.
- 
- ☐ 559. [5776427](#). 01 Jun 95; 07 Jul 98. Methods for targeting the vasculature of solid tumors. Thorpe; Philip E., et al. 424/1.49; 424/138.1 424/143.1 424/145.1 424/178.1 424/179.1 424/181.1 424/183.1 424/93.21 530/387.2 530/388.2 530/388.73 530/391.7. A61K051/10 A61K035/395 C07K016/00.
- 
- ☐ 560. [5773418](#). 20 Nov 97; 30 Jun 98. Fibrin sealant compositions and methods for utilizing same. Edwardson; Peter A. D., et al. 514/21; 424/529 424/94.64 514/12 530/382. A61K035/14 A61K038/36.
- 
- ☐ 561. [5770688](#). 06 Jun 95; 23 Jun 98. Method and composition for the treatment of mammalian HIV infection. Saermark; Torben, et al. 530/324;. A67K038/16.
- 
- ☐ 562. [5770194](#). 25 May 95; 23 Jun 98. Fibrin sealant compositions and methods for utilizing same. Edwardson; Peter A. D., et al. 424/94.64; 424/529 424/530 514/2 514/21 530/382. A61K038/48.
- 
- ☐ 563. [5767072](#). 21 Dec 93; 16 Jun 98. Therapeutic compositions comprising a CD4 peptide and

methods of treatment of HIV infections. Vitetta; Ellen S., et al. 514/12; 424/185.1 424/193.1 424/194.1 514/13 514/8 530/391.7 530/391.9 530/402. A61K038/10 A61K038/16.

---

☐ 564. 5763411. 02 Jun 95; 09 Jun 98. Nondynamic fibrin monomer on bandages, sutures, prostheses and dressings. Edwardson; Peter A. D., et al. 514/21; 424/443 424/445 424/447 424/529 424/530 514/12 530/382 602/41 602/42 602/43 602/48. A61K038/36.

---

☐ 565. 5763410. 02 Jun 95; 09 Jun 98. Kit for preparing a fibrin sealant. Edwardson; Peter A. D., et al. 514/21; 424/529 424/530 424/682 435/212 514/12 530/381 530/382. A61K038/36.

---

☐ 566. 5762926. 05 Jun 95; 09 Jun 98. Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system. Gage; Fred H., et al. 424/93.21; 435/320.1 435/375 435/69.1 514/44. C12N005/00 C12N015/09 C12N015/79 A61K048/00.

---

☐ 567. 5756095. 05 Jun 95; 26 May 98. Antibodies with specificity for a common epitope on E-selectin and L-selectin. Jutila; Mark A.. 424/144.1; 424/143.1 424/152.1 424/153.1 424/154.1 424/172.1 424/173.1 435/449 435/452 435/7.1 435/7.2 435/7.21 435/7.24 435/70.21 530/388.2 530/388.22 530/388.73 530/388.75 530/389.6. A61K039/395 C07K016/28 G01N033/53.

---

☐ 568. 5753640. 29 Dec 95; 19 May 98. Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome. Araneo; Barbara A., et al. 514/178;. A61K031/56.

---

☐ 569. 5753491. 06 Jun 95; 19 May 98. Use of neuro-derived fetal cell lines for transplantation therapy. Major; Eugene O., et al. 435/368; 424/93.21 435/320.1 514/44. A61K048/00 C12N005/00 C12N015/00.

---

☐ 570. 5750657. 18 Oct 93; 12 May 98. Methods and compositions using fibrin monomer to make a fibrin sealant. Edwardson; Peter A. D., et al. 530/382; 424/529 424/530 424/94.64 435/212 435/214 435/217 530/381 530/383 530/384. A61K035/14 A61K038/36.

---

☐ 571. 5750367. 08 Nov 93; 12 May 98. Human and mouse very low density lipoprotein receptors and methods for use of such receptors. Chan; Lawrence C. B.. 435/69.1; 435/243 435/320.1 435/325 435/410 435/69.6 435/70.1 435/70.3 435/71.1 536/23.1 536/23.5 536/24.1. C07H021/02 C12N005/00 C12N015/12 C12P021/06.

---

☐ 572. 5746223. 11 Oct 96; 05 May 98. Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis. Williams; Kevin Jon. 128/898; 604/522. A61B019/00.

---

☐ 573. 5739288. 26 May 95; 14 Apr 98. Fibrin sealant compositions. Edwardson; Peter A. D., et al. 530/382; 424/529 424/530 514/12 514/21 530/380 530/381. A61K035/14.

---

☐ 574. 5739118. 01 Apr 94; 14 Apr 98. Compositions and methods for delivery of genetic material. Carrano; Richard A., et al. 514/44; 424/184.1 424/278.1 435/375 435/69.1 435/69.3 514/25 514/27 514/33 514/35 514/510 514/54 514/680 514/731 514/732. A61K048/00 C07H015/24 C12N015/64 C12N015/87.

---

☐ 575. 5736157. 11 Oct 96; 07 Apr 98. Method of regulating cholesterol related genes, enzymes and other compounds, and pharmaceutical compositions. Williams; Kevin Jon. 424/450; 435/91.1.

---



A61K031/01.

---

☐ 576. 5733762. 31 Oct 96; 31 Mar 98. Complexes of nucleic acid and polymer, their process of preparation and their use for the transfection of cells. Midoux; Patrick, et al. 435/458; 435/325 514/44 530/300 530/345 530/350 530/395 530/402 536/23.2 536/23.5 536/23.7 536/24.5. C07K001/00 C07K001/107 C12N015/00 C12N015/88.

---

☐ 577. 5728707. 21 Jul 95; 17 Mar 98. Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide. Wehrmann; Felix. 514/274; 424/85.4 424/85.7 514/2 514/21 514/386. A61K031/415 A61K031/505.

---

☐ 578. 5720936. 29 Jul 94; 24 Feb 98. Transgenic mouse assay for compounds affecting amyloid protein processing. Wadsworth; Samuel, et al. 424/9.1; 800/3. A61K049/00 C12N005/00 C12N015/00.

---

☐ 579. 5720720. 15 Mar 96; 24 Feb 98. Convection-enhanced drug delivery. Laske; Douglas W., et al. 604/500; 604/21. A61M031/00.

---

☐ 580. 5716981. 07 Jun 95; 10 Feb 98. Anti-angiogenic compositions and methods of use. Hunter; William L., et al. 514/449; 128/898 526/304 528/421 604/20 604/21 604/269 604/508 606/198 623/1.15. A61K031/335 A61M029/00.

---

☐ 581. 5716614. 05 Aug 94; 10 Feb 98. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier. Katz; Robert, et al. 424/94.3; 424/130.1 424/283.1 514/2. A61K038/54 A61K039/395 A61K045/00 A61K038/00.

---

☐ 582. 5716404. 16 Dec 94; 10 Feb 98. Breast tissue engineering. Vacanti; Joseph P., et al. 623/8; 128/898. A61F002/12.

---

☐ 583. 5714511. 31 Jul 95; 03 Feb 98. Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs. Saavedra; Joseph E., et al. 514/426; 514/149 514/238.2 514/255.01 514/314 514/492 514/494 514/499 514/558 514/563 514/564 514/601 514/610 514/611 514/647 514/649. A61K031/40 A61K031/655 A61K031/535 A61K031/495 A61K031/47 A61K031/28 A61K031/315 A61K031/30 A61K031/20 A61K031/195 A61K031/18 A61K031/04 A61K031/13 A61K031/135.

---

☐ 584. 5714459. 07 Jun 95; 03 Feb 98. Use of prosaposin and neurotrophic peptides derived therefrom. O'Brien; John S., et al. 514/2; 514/12 514/13 514/8. A61K038/10 A61K038/18.

---

☐ 585. 5709854. 30 Apr 93; 20 Jan 98. Tissue formation by injecting a cell-polymeric solution that gels in vivo. Griffith-Cima; Linda, et al. 424/93.7; 424/426 435/178 435/182 435/395 435/396 435/397. C12N005/08 C12N005/06 C12N011/10 C12N011/04.

---

☒ 586. 5707969. 07 Jun 95; 13 Jan 98. Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor. Nabel; Elizabeth G., et al. 514/44; 435/320.1 435/6 435/69.1. C12N015/63 C12N015/79 C12N015/09 H61K048/00.

---

☐ 587. 5707604. 07 Jun 95; 13 Jan 98. Vivo agents comprising metal-ion chelates with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism,

---

sensitivity and kinetic-spatial profiles. Ranney; David F.. 424/9.35; 424/9.42 424/9.5 436/173 514/54 514/56 514/836. A61B005/055.

---

☐ 588. 5705388. 23 Dec 94; 06 Jan 98. CETP Ribozymes. Couture; Larry, et al. 435/366; 435/320.1 435/325 435/6 435/91.31 514/44 536/23.1 536/23.2 536/24.5. C12N015/85 C12Q001/68.

---

☐ 589. 5703048. 26 May 95; 30 Dec 97. Protection against liver damage by HGF. Roos; Filip, et al. 514/12; 435/360 514/2 514/838 514/893 514/894 530/350 530/399. A61K038/18 C07K014/475 C12N015/12 C07H021/04.

---

☐ 590. 5700909. 21 Apr 94; 23 Dec 97. Prosaposin and cytokine-derived peptides. O'Brien; John S.. 530/326; 530/327. C07K014/52.

---

☐ 591. 5698531. 23 Jan 95; 16 Dec 97. Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor. Nabel; Elizabeth G., et al. 514/44; 435/320.1 435/456 435/458 435/6 435/69.1. C12N015/63 C12N015/79 C12N015/09 A61K048/00.

---

☐ 592. 5698436. 06 Jun 95; 16 Dec 97. Introduction and expression of foreign genetic material in epithelial cells. Morgan; Jeffrey R., et al. 435/371; 424/93.4. C12N015/85 C12N015/56 C12N015/00.

---

☐ 593. 5696230. 31 Aug 94; 09 Dec 97. High-affinity response-selective C-terminal analogs of C5a anaphylatoxin. Sanderson; Sam D., et al. 530/328;. A61K038/00 A61K038/02 C07K005/00 C07K007/00.

---

☐ 594. 5696080. 07 Jun 95; 09 Dec 97. Pharmaceutical compositions comprising neurotrophic peptides derived from prosaposin. O'Brien; John S., et al. 514/2; 514/12 514/13 530/324 530/326. A61K038/18 C07K014/475.

---

☐ 595. 5690927. 02 Jun 95; 25 Nov 97. Use of neuro-glial fetal cell lines for transplantation therapy. Major; Eugene O., et al. 424/93.21; 424/570 424/582 424/93.2 424/93.7. C12N005/10.

---

☐ 596. 5688773. 28 Oct 94; 18 Nov 97. Method of selectively destroying neoplastic cells. Chiocca; E. Antonio, et al. 514/44; 424/93.1 424/93.21 435/320.1. A61K048/00 C12N005/00 C12N015/00 C07N014/00.

---

☐ 597. 5688640. 10 Aug 94; 18 Nov 97. Methods of screening of effectors of endothelin converting enzyme-1. Yanagisawa; Masashi. 435/6; 435/24 435/252.3 435/29 435/69.1. C12N015/63 C12Q001/68.

---

☐ 598. 5684133. 30 Aug 89; 04 Nov 97. Neurite growth regulatory factors, antibodies thereto, and pharmaceutical compositions. Schwab; Martin E., et al. 530/350; 435/70.21 436/519 436/548 530/387.9 530/388.24 530/399. C07K014/48 C07K016/22.

---

☐ 599. 5679339. 27 Jun 95; 21 Oct 97. Method of using IL-11 for treating spondyloarthropies. Keith; James, et al. 424/85.2; 530/351. A61K045/05 C07K017/00.

---

☐ 600. 5676943. 25 May 95; 14 Oct 97. Compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisulatory capsules. Baetge; Edward E., et al. 424/93.21; 424/93.3. A01N063/00 C62N015/00.

---

Generate Collection
---------------------

Print
-------

[Generate Collection](#)[Print](#)**Search Results - Record(s) 601 through 650 of 662 returned.**

- 
- ☐ 601. [5672334](#). 29 Nov 93; 30 Sep 97. In vivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans. Ranney; David F.. 424/9.34; 424/450 424/85.1 424/85.2 436/173 436/806. A61B005/055.
- 
- ☐ 602. [5668125](#). 28 Dec 95; 16 Sep 97. Use of aldosterone antagonists to inhibit myocardial fibrosis. Weber; Karl T.. 514/175; 514/173. A61K031/71.
- 
- ☐ 603. [5668124](#). 28 Mar 96; 16 Sep 97. Use of aldosterone antagonists to inhibit myocardial fibrosis. Weber; Karl T.. 514/175; 514/173. A61K031/71.
- 
- ☐ 604. [5663155](#). 30 Nov 94; 02 Sep 97. Compositions for the treatment of parasitic infections. McCaffrey; Ronald P., et al. 514/45; 514/46 536/27.21 536/27.6 536/27.61 536/27.62 536/27.63 536/27.7 536/27.8 536/27.81. A61K031/70 C07H019/16.
- 
- ☐ 605. [5661126](#). 07 Jul 94; 26 Aug 97. Use of mullerian inhibiting substance for treating certain tumors and for modulating class I major histocompatibility antigen expression. Donahoe; Patricia K., et al. 514/12; 435/68.1 435/69.1 530/413. A61K038/17 A61K038/18 C07K001/12.
- 
- ☐ 606. [5660827](#). 01 Jun 95; 26 Aug 97. Antibodies that bind to endoglin. Thorpe; Philip E., et al. 424/152.1; 424/130.1 424/138.1 424/141.1 530/387.1 530/388.1. A61K039/395 C07K016/00.
- 
- ☐ 607. [5656481](#). 25 May 95; 12 Aug 97. Compositions and methods for the delivery of biologically active molecules using cells contained in biocompatible capsules. Baetge; Edward E., et al. 435/325; 424/93.1 424/93.2 424/93.21 424/93.3 424/93.7 435/347 435/373 435/382. C12N015/00 C12N005/00 A01N063/00.
- 
- ☐ 608. [5654404](#). 10 Apr 95; 05 Aug 97. Protection against liver damage by HGF. Roos; Filip, et al. 530/387.3; 424/134.1 424/136.1 424/178.1 530/350. C07K014/435 C12P021/08 A61K039/00 A61K038/16.
- 
- ☐ 609. [5653975](#). 25 May 95; 05 Aug 97. Compositions and methods for the delivery of biologically active molecules using cells contained in biocompatible capsules. Baetge; Edward E., et al. 424/93.1; 424/93.2 424/93.21 424/93.3 424/93.7. C12N015/00 C12N005/00 A01N063/00.
- 
- ☐ 610. [5650148](#). 10 Mar 94; 22 Jul 97. Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system. Gage; Fred H., et al. 424/93.2; 424/93.21 435/948 514/44. A61K048/00 A61K031/00 C12N015/00 C12N005/00.
- 
- ☐ 611. [5639275](#). 25 May 95; 17 Jun 97. Delivery of biologically active molecules using cells contained in biocompatible immunoisulatory capsules. Baetge; Edward E., et al. 604/891.1; 424/422 424/424 424/93.1 424/93.2 435/325. A61K009/22 C12N015/00 C12N005/00 A01N063/00.
- 
- ☐ 612. [5618925](#). 03 Feb 95; 08 Apr 97. Extracts of shark cartilage having an anti-angiogenic activity and an effect on tumor regression; process of making thereof. Dupont; Eric, et al. 530/400; 530/350
-

530/412 530/414 530/415 530/417 530/418 530/427. C07K001/00 A23J001/00.

---

☐ 613. 5604131. 17 Sep 93; 18 Feb 97. cDNA-genomic DNA hybrid sequence encoding APP770 containing a genomic DNA insert of the KI and OX-2 regions. Wadsworth; Samuel, et al. 435/320.1; 536/23.5 536/24.1. C07H021/04 C12N015/12 C12N015/63.

---

☐ 614. 5599670. 21 Feb 95; 04 Feb 97. .beta.-glucuronidase and glucuronide permease gene system. Jefferson; Richard A.. 435/6; 435/183 435/200 435/252.3 435/252.33 435/320.1 435/325 435/418 435/419 435/455 435/468 435/469 435/476 514/44 536/23.2 536/23.7 536/24.1. C12Q001/68 C12N009/00 C12N009/24 A61K048/00.

---

☐ 615. 5585112. 30 Nov 93; 17 Dec 96. Method of preparing gas and gaseous precursor-filled microspheres. Unger; Evan C., et al. 424/450; 264/4.1 264/4.3 424/9.51. A61K009/127.

---

☐ 616. 5580781. 06 Apr 95; 03 Dec 96. Three-dimensional tumor cell and tissue culture system. Naughton; Gail K., et al. 435/1.1; 424/443 424/529 424/530 424/534 424/572 424/93.7 435/29 435/32 435/34 435/347 435/373 435/395 435/399 435/402. C12N005/00.

---

☐ 617. 5578485. 06 Apr 95; 26 Nov 96. Three-dimensional blood-brain barrier cell and tissue culture system. Naughton; Gail K., et al. 435/32; 424/422 424/484 424/572 424/93.7 435/1.1 435/1.2 435/284.1 435/289.1 435/29 435/396 435/397 435/399. C12N005/00 C12Q001/02 A01N001/02.

---

☐ 618. 5571787. 30 Jul 93; 05 Nov 96. Prosaposin as a neurotrophic factor. O'Brien; John S., et al. 514/12; 435/375 514/13 514/2 514/8 530/350 530/399. A61K038/17 A61K038/18 C12N015/00.

---

☐ 619. 5567612. 27 Jul 93; 22 Oct 96. Genitourinary cell-matrix structure for implantation into a human and a method of making. Vacanti; Joseph P., et al. 435/366; 424/422 424/423 424/426 424/486 424/93.7 435/1.1 623/915. C12N005/00 A01N001/02 A01N063/00 A61F002/02 A61F002/04 A61F013/00 A61F002/00 A61K009/14.

---

☐ 620. 5548062. 26 Nov 93; 20 Aug 96. Tumor cell invasion-inhibiting peptides, peptide complexes and cancer metastasis inhibitors. Isoai; Atsushi, et al. 530/326; 530/327 530/328 530/329 530/345. A61K038/00 A61K038/04 C07K005/00 C07K007/00.

---

☐ 621. 5541107. 06 Apr 95; 30 Jul 96. Three-dimensional bone marrow cell and tissue culture system. Naughton; Gail K., et al. 435/29; 424/422 424/484 424/572 435/1.1 435/284.1 435/289.1 435/32 435/347. C12N005/00 C12Q001/02 A01N001/02.

---

☐ 622. 5530114. 03 Apr 92; 25 Jun 96. Oligonucleotide modulation of arachidonic acid metabolism. Bennett; Clarence F., et al. 536/24.3; 435/6 536/24.1. C07H021/04 A61K048/00 C12Q001/68.

---

☐ 623. 5529992. 02 Dec 93; 25 Jun 96. Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldosterone receptors. Weber; Karl T.. 514/175; 514/173. A61K031/71.

---

☐ 624. 5527527. 15 Jan 93; 18 Jun 96. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates. Friden; Phillip M.. 424/178.1; 530/391.1 530/391.7 530/399. A61K039/44 C07K014/48 C07K016/46 C07K017/02.

---

- ☐ 625. 5518915. 06 Apr 95; 21 May 96. Three-Dimensional mucosal cell and tissue culture system. Naughton; Gail K., et al. 424/422; 424/484 424/572 435/1.1 435/284.1 435/29 435/32 435/371 435/373 435/399. C12N005/00 C12Q001/02 A04N001/02.
- 
- ☐ 626. 5516681. 06 Apr 95; 14 May 96. Three-dimensional pancreatic cell and tissue culture system. Naughton; Gail K., et al. 435/353; 424/422 424/484 424/572 435/1.1 435/1.2 435/284.1 435/29 435/32 435/347 435/373. C12N005/00 C12Q001/02 A01N001/02.
- 
- ☐ 627. 5516680. 06 Apr 95; 14 May 96. Three-dimensional kidney cell and tissue culture system. Naughton; Gail K., et al. 435/369; 424/422 424/484 424/572 435/1.1 435/1.2 435/284.1 435/29 435/32. C12N005/00 C12Q001/02 A01N001/02.
- 
- ☐ 628. 5512475. 06 Apr 95; 30 Apr 96. Three-dimensional skin cell and tissue culture system. Naughton; Gail K., et al. 424/484; 424/422 424/572 435/1.1 435/29 435/32. C12N005/00 C12Q001/02 A01N001/02.
- 
- ☐ 629. 5492915. 06 Oct 94; 20 Feb 96. Substituted quinolyl compounds exhibiting selective leukotriene B.sub.4 antagonist activity. Dereu; Norbert, et al. 514/311; 514/312 514/313 514/314 546/155 546/156 546/157 546/159 546/162 546/167 546/169 546/173 546/175 546/176 546/177 546/179 546/180. A61K031/47 C07D215/14 C07D215/227 C07D215/38.
- 
- ☐ 630. 5478739. 23 Oct 92; 26 Dec 95. Three-dimensional stromal cell and tissue culture system. Slivka; Sandra R., et al. 435/399; 623/915. C12N005/00 A61F002/10.
- 
- ☐ 631. 5464815. 06 Jun 94; 07 Nov 95. Inhibition of heparin-binding. Chamow; Steven, et al. 514/8; 424/85.2 436/86 436/87 514/21 530/412. A61K038/17 A61K038/18 C07K001/14 G01N033/68.
- 
- ☐ 632. 5443950. 04 Oct 93; 22 Aug 95. Three-dimensional cell and tissue culture system. Naughton; Gail K., et al. 435/1.1; 424/529 424/530 424/534 424/572 424/574 623/915. C12N005/08 C12N005/22 C12N011/14 C12N011/00.
- 
- ☐ 633. 5432081. 15 Oct 93; 11 Jul 95. Host cells transformed with the E. coli glucoronide permease gene. Jefferson; Richard A.. 435/325; 435/183 435/252.3 435/252.33 435/320.1. C12N001/21 C12N005/10.
- 
- ☐ 634. 5366982. 17 Feb 93; 22 Nov 94. Substituted bicyclic bis-aryl compounds exhibiting selective leukotriene B.sub.4 antagonist activity, their preparation and use in pharmaceutical compositions. Dereu; Norbert, et al. 514/340; 514/347 514/349 514/351 514/352 546/290 546/296 546/297 546/298 546/299 546/300 546/301 546/303 546/304 546/309 546/314 546/329 546/330 546/340. A61K031/44 C07D213/62 C07D213/64 C07D401/12.
- 
- ☐ 635. 5330897. 19 May 92; 19 Jul 94. Sialic acid binding lectin of protozoan origin. Pindak; Frank F., et al. 435/7.23; 435/7.2 435/7.21 435/7.24 435/7.9 435/7.94 436/501 436/63 436/64 436/813 436/827. G01N033/574 G01N033/566 G01N033/567.
- 
- ☒ 636. 5328470. 26 Jul 91; 12 Jul 94. Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor. Nabel; Elizabeth G., et al. 604/101.03; 606/194. A61M029/00.
-

- ☐ 637. 5320846. 22 Oct 92; 14 Jun 94. Method and composition for testing patients with metabolic depleting diseases. Bistrian; Bruce R., et al. 424/439; 514/46 514/838 514/893 514/894. A61K047/00.
- 
- ☐ 638. 5268463. 08 Dec 89; 07 Dec 93. Plant promoter .alpha.-glucuronidase gene construct. Jefferson; Richard A.. 536/23.7; 435/200 435/320.1 536/24.1. C12N015/56 C12N015/82.
- 
- ☐ 639. 5266480. 30 Aug 90; 30 Nov 93. Three-dimensional skin culture system. Naughton; Gail K., et al. 435/371; 435/372. C12N005/00 C12M003/00.
- 
- ☐ 640. 5260050. 11 Jan 90; 09 Nov 93. Methods and compositions for magnetic resonance imaging comprising superparamagnetic ferromagnetically coupled chromium complexes. Ranney; David F.. 424/9.351; 424/617 424/9.35 436/173 436/806 536/102 536/112 536/122 556/61 600/420. G01N024/08 C07F019/00 C07H023/00 A61K033/24.
- 
- ☐ 641. 5250414. 24 Jun 91; 05 Oct 93. Diagnostic methods using neurite growth regulatory factors. Schwab; Martin E., et al. 435/7.72; 435/7.23 436/64 436/813 514/2 514/21 530/350. C12N009/64.
- 
- ☐ 642. 5221607. 29 Oct 91; 22 Jun 93. Assays and reagents for amyloid deposition. Cordell; Barbara, et al. 435/6; 435/320.1 435/7.21 435/70.1 435/70.3 436/811 530/300 530/350 530/806 530/839 536/23.5. C12Q001/68 C07K013/00 C12N015/00.
- 
- ☐ 643. 5213788. 04 Apr 91; 25 May 93. Physically and chemically stabilized polyatomic clusters for magnetic resonance image and spectral enhancement. Ranney; David F.. 424/9.322; 424/617 424/9.35 436/173 436/806 514/56 514/836 600/420. G01N024/08 C07H023/00 A61K033/24 A61K031/725.
- 
- ☐ 644. 5202120. 27 Oct 89; 13 Apr 93. Methods of reducing glial scar formation and promoting axon and blood vessel growth and/or regeneration through the use of activated immature astrocytes. Silver; Jerry, et al. 424/93.7; 424/425 424/570 435/368. A61K035/12 C12N005/06.
- 
- ☐ 645. 5188828. 08 Nov 90; 23 Feb 93. Interleukin-6 to stimulate erythropoietin production. Goldberg; Mark A., et al. 424/85.2; 514/12 514/8 530/351. A61K045/05 C07K013/00.
- 
- ☐ 646. 5182107. 06 Mar 92; 26 Jan 93. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates. Friden; Phillip M.. 424/179.1; 424/143.1 424/178.1 424/94.1 514/21 530/387.3 530/388.22 530/391.1 530/391.7 530/391.9 530/399. A61K039/44 A61K037/36 C07K017/02 C07K015/28.
- 
- ☐ 647. 5160490. 21 Feb 91; 03 Nov 92. Three-dimensional cell and tissue culture apparatus. Naughton; Gail K., et al. 435/287.1; 435/29 435/32 436/63. C12M001/00 C12Q001/18 C12N005/06.
- 
- ☐ 648. 5120537. 14 Jun 89; 09 Jun 92. Factor Xa based anticoagulant compositions. Esmon; Charles T., et al. 424/94.64; 435/212 435/226 435/69.6 514/12 514/2 514/21 530/381. A61K037/547 A61K037/02 C12N015/01 C07K013/00.
- 
- ☐ 649. 5116615. 30 May 91; 26 May 92. Method for treating benign prostatic hypertrophy. Gokcen; Muharrem, et al. 424/94.2; 424/94.21 424/94.6 424/94.61 424/94.62 424/94.63 424/94.64 424/94.65 424/94.67. A61K037/62 A61K037/547 A61K037/54 A61K.
- 
- ☐ 650. 5032508. 01 Sep 89; 16 Jul 91. Three-dimensional cell and tissue culture system. Naughton;